Rituximab in renal transplantation

Transplant International

Volumn 26, Issue 6, 2013, Pages 563-575

  Barnett, A Nicholas R ^a,b   Hadjianastassiou, Vassilis G ^a,b,c   Mamode, Nizam ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NICOSIA GENERAL HOSPITAL   (Cyprus)

Author keywords

B lymphocytes; CD20 antigens; graft rejection; immunosuppression; kidney transplantation; monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; OKT 3; PLACEBO; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; B LYMPHOCYTE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; CARDIOVASCULAR DISEASE; CHRONIC GRAFT REJECTION; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DRUG MECHANISM; GRAFT SURVIVAL; HEPATITIS B; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFECTION RATE; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NEUTROPENIA; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SPLENECTOMY; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; BLOOD GROUP INCOMPATIBILITY; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84878018444     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12072     Document Type: Review

References (101)

1. Roche Products Limited. Summary of Product Characteristics: Mabthera 100 mg and 500 mg concentrate for solution for infusion (last updated on the eMC 15/06/2012). Available at: http://www.medicines.org.uk/emc/medicine/2570. Accessed 17 July 2012.
2. Tedder TF, Engel P,. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450.
3. Taylor RP, Lindorfer MA,. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007; 3: 86.
4. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G,. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418.
5. Sawada T, Fuchinoue S, Teraoka S,. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207.
6. Uchida J, Kuwabara N, Machida Y, et al,. Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience. Transplant Proc 2012; 44: 204.
7. Tyden G, Kumlien G, Fehrman I,. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730.
8. Sonnenday CJ, Warren DS, Cooper M, et al,. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
9. Gloor JM, Lager DJ, Fidler ME, et al,. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80: 1572.
10. Saito K, Nakagawa Y, Suwa M, et al,. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006; 13: 111.
11. Chikaraishi T, Sasaki H, Tsutsumi H, et al,. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab. Transplant Proc 2008; 40: 3445.
12. Galliford J, Charif R, Chan KK, et al,. ABO incompatible living renal transplantation with a steroid sparing protocol. Transplantation 2008; 86: 901.
13. Haidinger M, Schmaldienst S, Kormoczi G, et al,. Vienna experience of ABO-incompatible living-donor kidney transplantation. Wien Klin Wochenschr 2009; 121: 247.
14. Oettl T, Halter J, Bachmann A, et al,. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant 2009; 24: 298.
15. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T,. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009; 162: 61.
16. Schousboe K, Titlestad K, Baudier F, Hansen LU, Bistrup C,. ABO-incompatible kidney transplantation. Dan Med Bull 2010; 57: A4197.
17. Wilpert J, Fischer K-G, Pisarski P, et al,. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010; 25: 3778.
18. Habicht A, Broker V, Blume C, et al,. Increase of infectious complications in ABO-incompatible kidney transplant recipients-a single centre experience. Nephrol Dial Transplant 2011; 26: 4124.
19. Genberg H, Kumlien G, Wennberg L, Tyden G,. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2011; 26: 2394.
20. Shirakawa H, Ishida H, Shimizu T, et al,. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011; 25: 878.
21. Fuchinoue S, Ishii Y, Sawada T, et al,. The 5-year outcome of abo-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91: 853.
22. Chung BH, Lee JY, Kang SH, et al,. Comparison of clinical outcome between high and low baseline anti-abo antibody titers in ABO-incompatible kidney transplantation. Ren Fail 2011; 33: 150.
23. Yoshimura N, Ushigome H, Matsuyama M, et al,. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment. Transplant Proc 2012; 44: 140.
24. Morath C, Becker LE, Leo A, et al,. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 2012; 93: 827.
25. Wilpert J, Geyer M, Pisarski P, et al,. On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorptions after ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2007; 22: 3048.
26. Mamode N, Hadjianastassiou V, Dorling A, Kenchayikoppad S, Barnett N,. Successful outcomes after minimising antibody modulation in blood group incompatible kidney transplantation. Transpl Int 2011; 24: 37.
27. NHS Blood and Transplant. Transplant Activity in the UK, Activity Report 2011/12, p. 83. Available at: http://www.organdonation.nhs.uk/statistics/ transplant-activity-report/. Accessed 14 September 2012.
28. Montgomery RA, Locke JE, King KE, et al,. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87: 1246.
29. Flint SM, Walker RG, Hogan C, et al,. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11: 1016.
30. Lawrence C, Galliford JW, Willicombe MK, et al,. Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic? Transplantation 2011; 92: 1129.
31. Gloor JM, DeGoey SR, Pineda AA, et al,. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017.
32. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET,. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc 2008; 40: 2218.
33. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S,. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 2008; 86: 96.
34. Yin H, Hu XP, Li XB, et al,. Protein A immunoadsorption combined with rituximab in highly sensitized kidney transplant recipients. Chin Med J (Engl) 2009; 122: 2752.
35. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
36. Vo AA, Peng A, Toyoda M, et al,. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
37. Yin H, Wan H, Hu XP, et al,. Rituximab induction therapy in highly sensitized kidney transplant recipients. Chin Med J (Engl) 2011; 124: 1928.
38. Morath C, Beimler J, Opelz G, et al,. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506.
39. de Wit J, Souwer Y, Jorritsma T, et al,. Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS One 2010; 5: e13016.
40. Bouaziz JD, Calbo S, Maho-Vaillant M, et al,. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol 2010; 40: 2686.
41. Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I,. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother 2012; 61: 1233.
42. Lehnhardt A, Mengel M, Pape L, Ehrich JH, Offner G, Strehlau J,. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant 2006; 6: 847.
43. Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S,. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 2005; 19: 137.
44. Moscoso-Solorzano GT, Baltar JM, Seco M, Lopez-Larrea C, Mastroianni-Kirsztajn G, Ortega F,. Single dose of Rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report. Transplant Proc 2007; 39: 3460.
45. Celik A, Saglam F, Cavdar C, et al,. Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report. Transplant Proc 2008; 40: 302.
46. Yang YW, Lin WC, Wu MS, Lee PH, Tsai MK,. Early diagnosis and successful treatment of acute antibody-mediated rejection of a renal transplant. Exp Clin Transplant 2008; 6: 211.
47. Vega J, Goecke H, Carrasco A, et al,. Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate. Clin Exp Nephrol 2011; 15: 308.
48. Becker YT, Becker BN, Pirsch JD, Sollinger HW,. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996.
49. Faguer S, Kamar N, Guilbeaud-Frugier C, et al,. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277.
50. Tanriover B, Wright SE, Foster SV, et al,. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc 2008; 40: 3393.
51. Mulley WR, Hudson FJ, Tait BD, et al,. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87: 286.
52. Gomes AM, Pedroso S, Martins LS, et al,. Diagnosis and treatment of acute humoral kidney allograft rejection. Transplant Proc 2009; 41: 855.
53. Rodriguez Ferrero M, Rincon A, Bucalo L, Rementeria A, Anaya F,. Treatment of acute antibody-mediated rejection: a single-center experience. Transplant Proc 2010; 42: 2848.
54. Kaposztas Z, Podder H, Mauiyyedi S, et al,. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63.
55. Lefaucheur C, Nochy D, Andrade J, et al,. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
56. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM,. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607.
57. Steinmetz OM, Lange-Husken F, Turner JE, et al,. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84: 842.
58. Thaunat O,. Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation 2011; 92: 121.
59. Billing H, Rieger S, Ovens J, et al,. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: 1214.
60. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A,. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837.
61. Rostaing L, Guilbeau-Frugier C, Fort M, Mekhlati L, Kamar N,. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int 2009a; 22: 906.
62. Study of Rituximab to Treat Chronic Renal Transplant Rejection (RituxiCAN-C4), NCT00476164. Available at: http://clinicaltrials.gov/ct2/show/ NCT00476164. Accessed 22 July 2012.
63. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K,. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469.
64. Tyden G, Genberg H, Tollemar J, et al,. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
65. Clatworthy MR, Watson CJE, Plotnek G, et al,. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683.
66. van den Hoogen MWF, Hilbrands LB,. More on B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 361: 1215.
67. ReMIND (RituxiMab INDuction in renal transplantation), NCT01095172. Available at: http://clinicaltrials.gov/ct2/show/NCT01095172. Accessed 23 July 2012.
68. Jagadeesh D, Woda BA, Draper J, Evens AM,. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122.
69. Evens AM, David KA, Helenowski I, et al,. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038.
70. Caillard S, Lelong C, Pessione F, Moulin B, French PWG,. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735.
71. Martin-Gomez MA, Pena M, Cabello M, et al,. Posttransplant lymphoproliferative disease: a series of 23 cases. Transplant Proc 2006; 38: 2448.
72. Abe T, Ichimaru N, Kokado Y, et al,. Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40 years. Int J Urol 2010; 17: 48.
73. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002; 17 (Suppl. 4): 31, 56.
74. Svoboda J, Kotloff R, Tsai DE,. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006; 19: 259.
75. Trappe R, Oertel S, Leblond V, et al,. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196.
76. Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner GL,. Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients. Am J Transplant 2011; 11: 1058.
77. Kumar D, Gourishankar S, Mueller T, et al,. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009; 11: 167.
78. Shelton E, Yong M, Cohney S,. Late onset pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009; 14: 696.
79. Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA,. Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant 2009; 23: 431.
80. Suzan F, Ammor M, Ribrag V,. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
81. Scemla A, Loupy A, Candon S, et al,. Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study. Transplantation 2010; 90: 1180.
82. Vo AA, Lukovsky M, Toyoda M, et al,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
83. Nishida H, Ishida H, Tanaka T, et al,. Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy. Transpl Int 2009; 22: 961.
84. Kahwaji J, Sinha A, Toyoda M, et al,. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894.
85. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K,. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010; 89: 1466.
86. Rostaing L, Guilbeau-Frugier C, Kamar N,. Rituximab for humoral rejection after kidney transplantation: an update. Transplantation 2009b; 87: 1261.
87. Grim SA, Pham T, Thielke J, et al,. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21: 628.
88. Kamar N, Milioto O, Puissant-Lubrano B, et al,. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
89. Drage M, Hadjianastassiou V, Dorling A, Mamode N,. Rituximab may not lead to increased infection rates in transplant recipients. Am J Transplant 2010; 10: 2723.
90. Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P,. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol 2009; 84: 247.
91. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A,. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an Anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 1999; 94: 2217.
92. Wolach O, Bairey O, Lahav M,. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89: 308.
93. Mitsuhata N, Fujita R, Ito S, Mannami M, Keimei K,. Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation. Transplantation 2005; 80: 1355.
94. Carson KR, Evens AM, Richey EA, et al,. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834.
95. Kamar N, Mengelle C, Rostaing L,. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009; 9: 244.
96. Dillman RO,. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18: 465.
97. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND,. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010; 25: 205.
98. Tyden G, Ekberg H, Tufveson G, Mjornstedt L,. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 2012; 94: e21.
99. Newell KA, Asare A, Kirk AD, et al,. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836.
100. Pallier A, Hillion S, Danger R, et al,. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503.
101. Silva HM, Takenaka MC, Moraes-Vieira PM, et al,. Preserving the B-cell compartment favors operational tolerance in human renal transplantation. Mol Med 2012; 18: 733.